Does minimal residual disease (MRD) predict relapse in children with advance B-NHL treated with chemoimmunotherapy: a children's oncology report

被引：0
|
作者：
Shiramizu, B. [1 ]
Goldman, S. [2 ]
Smith, L. [3 ]
Harrison, L. [4 ]
Van de Ven, C. [4 ]
Gross, T. [5 ]
Sanger, W. [6 ]
Perkins, S. [7 ]
Cairo, M. [4 ,8 ,9 ,10 ,11 ]
机构：
[1] Univ Hawaii, Honolulu, HI 96822 USA
[2] Med City Childrens Hosp, Dallas, TX USA
[3] Childrens Oncol Grp, Ctr Data, Omaha, NE USA
[4] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA
[5] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA
[6] Univ Nebraska, Omaha, NE 68182 USA
[7] Univ Utah, Salt Lake City, UT USA
[8] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[9] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA
[10] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA
[11] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
101
引用
收藏
页码：53 / 53
页数：1
相关论文
共 50 条
  • [1] MINIMAL DISSEMINATED DISEASE/RESIDUAL DISEASE IN CHILDREN AND ADOLESCENTS WITH MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL) MAY IMPACT THE RISK OF RELAPSE: A CHILDREN'S ONCOLOGY GROUP REPORT
    Shiramizu, B.
    Goldman, S.
    Smith, L.
    Harrison, L.
    Van De Ven, C.
    Gross, T. G.
    Sanger, W.
    Perkins, S.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 114 - 114
  • [2] Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report.
    Shiramizu, B.
    Goldman, S.
    Kusao, I.
    Agsalda, M.
    Lynch, J. C.
    Harrison, L.
    Gross, T. G.
    Sanger, W.
    Perkins, S. L.
    Cairo, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Flow cytometry detection of minimal residual disease (MRD) in children treated for AML
    Bjorklund, E
    Porwit-Macdonald, A
    Soderhall, S
    CYTOMETRY PART A, 2004, 59A (01): : 135 - 135
  • [4] Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) in relapse. A children's oncology group (COG) study.
    Borowitz, MJ
    Devidas, M
    Hunger, SP
    Carroll, WL
    Raetz, E
    BLOOD, 2004, 104 (11) : 96A - 96A
  • [5] Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report
    Galardy, Paul J.
    Hochberg, Jessica
    Perkins, Sherrie L.
    Harrison, Lauren
    Goldman, Stanton
    Cairo, Mitchell S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (03) : 365 - 372
  • [6] Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab plus FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    van de Ven, Carmella
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Goldman, Stanton
    BLOOD, 2008, 112 (11) : 310 - 310
  • [7] Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group
    Davies, Stella M.
    Borowitz, Michael J.
    Rosner, Gary L.
    Ritz, Kristin
    Devidas, Meenakshi
    Winick, Naomi
    Martin, Paul L.
    Bowman, Paul
    Elliott, James
    Willman, Cheryl
    Das, Soma
    Cook, Edwin H.
    Relling, Mary V.
    BLOOD, 2008, 111 (06) : 2984 - 2990
  • [8] OUTCOME AND PHARMACOKINETIC (PK) ANALYSIS OF ADDING RITUXIMAB TO FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS WITH ADVANCED MATURE B-NHL/LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP REPORT
    Goldman, Stan
    Smith, Lynette
    Perkins, Sherrie
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren
    Harrison, Lauren
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 737 - 738
  • [9] Safety and pharmacokinetics of rituximab in combination with FAB chemotherapy in children and adolescents with Stage III/IV mature B-NHL and B-cell leukemia ± CNS disease: a Children's Oncology Group Report
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 23 - 23
  • [10] Prognostic significance of minimal residual disease (MRD) in children with high risk acute lymphoblastic leukemia(ALL). A children's oncology group study.
    Borowitz, MJ
    Devidas, M
    Bowman, WP
    Larsen, E
    Pullen, J
    Camitta, B
    BLOOD, 2005, 106 (11) : 29A - 29A
12345